Chimeric antigen receptor T cells secreting IL-12 and anti-IL-6 to enhance responses in multiple myeloma

Basic Information

Funding Cycle : 2021-2022, 2022-2023
Name : Kevin Hay
Type of Award : Translational Research Award
Home Institution : Terry Fox Laboratory, BC Cancer Research Institute, Canada


The study aims to enhance the efficacy of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) by engineering CAR-T cells to secrete interleukin-12 (IL-12) and an anti-IL-6 single domain antibody (sdAb). While current CAR-T therapies targeting BCMA show promising response rates, median progression-free survival remains short, indicating the need for improved strategies. The hypothesis is that the engineered CAR-T cells will repolarize microenvironment macrophages and myeloid-derived suppressor cells, thereby enhancing efficacy against MM. The study plans to engineer these modified CAR-T cells and assess their function in vitro, evaluate their efficacy using myeloma cell line/macrophage co-culture systems, and characterize their efficacy and toxicity in an immunocompetent murine model of MM. This approach aims to address challenges in CAR-T cell therapy failure and improve treatment outcomes for MM patients.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events